BELLUS Health to Present at Jefferies Global Healthcare Conference in London
LAVAL, Quebec--(BUSINESS WIRE)--Nov 13, 2019--
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will present a corporate overview of the Company on Wednesday, November 20, 2019 at the Jefferies Global Healthcare Conference in London.
Event: Jefferies Global Healthcare Conference in London
Date/Time: Wednesday, November 20, 2019 at 9:20 a.m. GMT
A live webcast may be accessed on the Events and Presentations page under the Investors & News section of BELLUS Health’s website at www.bellushealth.com. Following the event, an archived webcast and presentation will be available on the Company’s website.
About BELLUS Health
BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191113005189/en/
Vice President, Finance
Joshua R. Mansbach
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH HEALTH PHARMACEUTICAL CLINICAL TRIALS
SOURCE: BELLUS Health Inc.
Copyright Business Wire 2019.
PUB: 11/13/2019 07:00 AM/DISC: 11/13/2019 07:01 AM